|
|
| | V-9302 HCl Basic information |
| Product Name: | V-9302 HCl | | Synonyms: | (S)-2-Amino-4-(bis(2-((3-methylbenzyl)oxy)benzyl)amino)butanoic acid hydrochloride | | CAS: | 2416138-42-4 | | MF: | C34H39ClN2O4 | | MW: | 575.15 | | EINECS: | | | Product Categories: | | | Mol File: | 2416138-42-4.mol |  |
| | V-9302 HCl Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: 250 mg/mL (434.68 mM) | | form | Solid | | color | White to off-white |
| | V-9302 HCl Usage And Synthesis |
| Uses | V-9302 hydrochloride is a competitive antagonist of transmembrane glutamine flux. V-9302 hydrochloride selectively and potently targets the amino acid transporter ASCT2 (SLC1A5) not ASCT1. V-9302 hydrochloride inhibits ASCT2-mediated glutamine uptake (IC50=9.6 μM) in HEK-293 cells[1]. | | in vivo | V-9302 hydrochloride (75 mg/kg; i.p.; daily fo 21 days) prevents tumor growth in both HCT-116 and HT29 xenograft models[1].
The combination of CB-839 and V-9302 (30 mg/kg; i.p.; SNU398 and MHCC97H cells were grown as tumor xenografts in BALB/c nude mice; for 20 or 15 d, respectively) elicits a strong growth inhibition in both SNU398 and MHCC97H xenograft models, while single-drug treatment showed modest anti-tumor effects[2].
V-9302 (50 mg/kg ; i.p.; daily for 5 days) displays markedly reduced tumor growth[3]. | Animal Model: | 6-week old, female athymic nude mice (bearing HCT-116 (KRASG13D) or HT29 (BRAFV600E) cell-line )[1] | | Dosage: | 75 mg/kg | | Administration: | Intraperitoneally; daily fo 21 days
| | Result: | Prevented tumor growth.
|
| | IC 50 | ASCT2 | | References | [1] Schulte ML, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacyin preclinical models. Nat Med. 2018 Feb;24(2):194-202. DOI:10.1038/nm.4464
[2] Jin H, et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. Elife. 2020;9:e56749. Published 2020 Oct 5. DOI:10.7554/eLife.56749
[3] Edwards DN, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021;131(4):e140100. DOI:10.1172/JCI140100 |
| | V-9302 HCl Preparation Products And Raw materials |
|